Middle East And Africa Liquid Biopsy Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
2023
2030
 Período de pronóstico |
2024 –2030 |
 Tamaño del mercado (año base) |
|
 Tamaño del mercado (año de pronóstico) |
|
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado de biopsia líquida en Oriente Medio y África, por producto (instrumentos, consumibles y accesorios, servicios y software), tipo de biofabricante ( células tumorales circulantes (CTCS) , ADN libre de células circulantes (CFDNA), ARN libre de células, vesículas extracelulares, exosomas y otros), tipo de muestra (basada en muestras de sangre, muestras de orina, muestras de saliva y otros fluidos tisulares y otros), tipo analítico (molecular, proteómica e histología/imágenes), tipo de aplicación (aplicaciones oncológicas y aplicaciones no oncológicas), aplicación clínica (detección de rutina, evaluación del paciente, selección de terapia, monitoreo del tratamiento, monitoreo de recurrencia y otros), tecnología (análisis paralelo de múltiples genes y análisis de un solo gen), usuario final (hospitales, laboratorios de referencia, centros de diagnóstico, centros de investigación e institutos académicos y otros), canal de distribución (licitación directa, distribuidor externo y otros) - Tendencias de la industria y Pronóstico hasta 2030.
Análisis y perspectivas del mercado de biopsia líquida en Oriente Medio y África
La creciente conciencia de la tecnología de diagnóstico avanzada en Oriente Medio y África ha aumentado la demanda del mercado. El aumento del gasto sanitario para mejorar los servicios sanitarios también contribuye al crecimiento del mercado. Los principales actores del mercado se centran en el lanzamiento y la aprobación de diversos servicios durante este período crucial. Además, el aumento de los avances en materia de procesos y técnicas también contribuye a la creciente demanda de biopsia líquida.
Se espera que el mercado de biopsia líquida de Oriente Medio y África crezca en el año de pronóstico debido al aumento de los actores del mercado y la disponibilidad de servicios avanzados. Junto con esto, los fabricantes están involucrados en la actividad de desarrollo para lanzar nuevos servicios en el mercado. El creciente desarrollo en el campo de las técnicas avanzadas de atención médica está impulsando aún más el crecimiento del mercado.
Sin embargo, dificultades como la falta de protocolos estandarizados y la falta de profesionales capacitados podrían obstaculizar el crecimiento del mercado de biopsia líquida de Medio Oriente y África en el período de pronóstico.
Data Bridge Market Research analiza que el mercado de biopsia líquida de Oriente Medio y África crecerá a una CAGR del 11,7% durante el período de pronóstico de 2023 a 2030.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Personalizable para 2015-2020) |
|
Unidades cuantitativas |
Ingresos en millones, volúmenes en unidades, precios en USD |
|
Segmentos cubiertos |
Producto (instrumentos, consumibles y accesorios, servicios y software), tipo de biofabricante (células tumorales circulantes [CTCS], ADN libre de células circulantes [CFDNA], ARN libre de células, vesículas extracelulares, exosomas y otros), tipo de muestra (basada en muestras de sangre, muestras de orina, muestras de saliva y otros fluidos tisulares y otros), tipo analítico (molecular, proteómica e histología/imágenes), tipo de aplicación (aplicaciones oncológicas y aplicaciones no oncológicas), aplicación clínica (examen de rutina, evaluación del paciente, selección de terapia, monitoreo del tratamiento, monitoreo de recurrencia y otros), tecnología (análisis paralelo de múltiples genes y análisis de un solo gen), usuario final (hospitales, laboratorios de referencia, centros de diagnóstico, centros de investigación e institutos académicos y otros), canal de distribución (licitación directa, distribuidor externo y otros) |
|
Países cubiertos |
Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto y el resto de Oriente Medio y África. |
|
Actores del mercado cubiertos |
F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (salud genómica), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC. y Sysmex Inostics Inc., entre otros. |
Definición de mercado
Una biopsia líquida es una prueba médica que implica el análisis de diversas biomoléculas, como ADN, ARN, proteínas y otras sustancias en la sangre u otros fluidos corporales de un paciente, para diagnosticar y controlar diversas afecciones médicas, incluido el cáncer. A diferencia de las biopsias tradicionales que implican la extracción de muestras de tejido del cuerpo, una biopsia líquida no es invasiva y puede proporcionar información diagnóstica importante sin la necesidad de cirugía u otros procedimientos invasivos. Las biopsias líquidas aún se encuentran en las primeras etapas de desarrollo, pero son prometedoras para mejorar la detección y el tratamiento del cáncer y otras enfermedades.
Dinámica del mercado de biopsia líquida en Oriente Medio y África
Esta sección trata sobre la comprensión de los factores impulsores del mercado, las ventajas, las oportunidades, las limitaciones y los desafíos. Todo esto se analiza en detalle a continuación.
Conductores
- Creciente demanda de técnicas de biopsia líquida no invasivas
Las biopsias líquidas consisten en aislar entidades derivadas de tumores, como células tumorales circulantes, ADN tumoral circulante y vesículas extracelulares tumorales, entre otras, presentes en los fluidos corporales de pacientes con cáncer, seguido de un análisis de los datos genómicos y proteómicos contenidos en ellas. Los métodos para el aislamiento y análisis de biopsias líquidas han evolucionado rápidamente en los últimos años, como se describe en la revisión, proporcionando así mayores detalles sobre las características tumorales, como mutaciones, estadificación tumoral, progresión tumoral, heterogeneidad y evolución genética y clonal, entre otras. Las biopsias líquidas de pacientes con cáncer han abierto nuevas vías en la detección y el seguimiento continuo, el tratamiento basado en la medicina de precisión y la detección de marcadores de resistencia terapéutica. Los diagnósticos no invasivos del cáncer ofrecen un enfoque más seguro y más amigable para el paciente, lo que resulta en una creciente demanda de estos métodos.
- Avances en la medicina de precisión gracias a la biopsia líquida
La oncología médica de precisión en el tratamiento clínico del cáncer se puede lograr a través de la plataforma de diagnóstico denominada "biopsia líquida" (LB). La LB fue reconocida como un poderoso enfoque en tiempo real para el monitoreo molecular de esta enfermedad oncológica dinámica. Este método utiliza la detección de biomarcadores en la sangre con fines de pronóstico y predicción por medios no invasivos, lo que en un futuro cercano representará un cambio en el paradigma de la comprensión de la biología molecular y la heterogeneidad de los tumores. Los avances en la medicina de precisión, impulsados por el uso de técnicas de biopsia líquida, han contribuido significativamente a la creciente demanda de diagnósticos no invasivos del cáncer. Las técnicas de biopsia líquida, como el análisis del ADN tumoral circulante (ctDNA), las células tumorales circulantes (CTC) o los exosomas en la sangre u otros fluidos corporales, brindan información valiosa sobre la composición genética de los tumores, lo que permite enfoques de medicina de precisión en el tratamiento del cáncer.
Oportunidad
- Integración de inteligencia artificial (IA) y aprendizaje automático
Los métodos basados en biopsia líquida ofrecen muchas nuevas oportunidades para medir biomarcadores moleculares con el fin de diagnosticar, pronosticar y monitorear enfermedades. La inteligencia artificial (IA), como el aprendizaje automático, y su capacidad para identificar características de estados patológicos específicos en datos multiplexados serán fundamentales para aprovechar la nueva información molecular que pueden extraer los diagnósticos basados en microchips.
Por lo tanto, se espera que la integración de la IA y el aprendizaje automático actúe como una oportunidad para el crecimiento del mercado.
- Aumentar los reembolsos y el apoyo gubernamental para la biopsia líquida
La adopción de la biopsia líquida ha sido influenciada significativamente por el respaldo gubernamental. Los gobiernos de todo el mundo han promulgado leyes para fomentar la adopción de la biopsia líquida porque entienden que puede mejorar la atención al paciente, reducir los costos de la atención médica y hacer avanzar la medicina de precisión. La incorporación de la biopsia líquida en los programas nacionales de detección del cáncer o en las recomendaciones de tratamiento es solo un ejemplo de cómo se podría hacer esto. Otros ejemplos incluyen la financiación de la investigación y el desarrollo de tecnologías de biopsia líquida y el respaldo de ensayos y estudios clínicos para producir evidencia sobre su eficacia terapéutica. Esta asistencia gubernamental ha ayudado a impulsar el conocimiento, la adopción y la cobertura de reembolso de la prueba de biopsia líquida.
Por lo tanto, se espera que el aumento de los reembolsos y el apoyo gubernamental a la biopsia líquida actúen como una oportunidad para el crecimiento del mercado.
Restricción/Desafío
- Alto costo de las pruebas de biopsia líquida
La biopsia líquida se ve seriamente limitada por su elevado coste. Si bien las pruebas de biopsia líquida son prometedoras para la detección y el seguimiento no invasivos de enfermedades, incluido el cáncer, existen obstáculos relacionados con el coste que pueden impedir su uso generalizado.
La necesidad de herramientas y tecnologías especializadas es uno de los mayores obstáculos económicos. Con frecuencia, se necesitan herramientas costosas, como máquinas de PCR digital, plataformas de NGS y sistemas de procesamiento automatizado de muestras, para los estudios de biopsia líquida. A los centros de salud más pequeños con presupuestos más ajustados puede resultarles difícil afrontar la inversión inicial y los costos de mantenimiento continuos relacionados con estas tecnologías, lo que limita su capacidad para proporcionar pruebas de biopsia líquida a los pacientes.
Por lo tanto, se espera que el alto costo de las pruebas de biopsia líquida restrinja el crecimiento del mercado.
- Falta de profesionales capacitados para realizar biopsia líquida
La demanda de pruebas de biopsia líquida está aumentando debido a su posible utilidad clínica en la detección y el seguimiento del cáncer y la toma de decisiones personalizadas sobre el tratamiento. Sin embargo, puede haber recursos limitados, incluidos personal, equipos y financiación, para respaldar la implementación de programas de biopsia líquida en instituciones de atención médica. Esto puede dar lugar a una escasez de profesionales capacitados que puedan realizar pruebas de biopsia líquida, especialmente en regiones o entornos de atención médica con recursos limitados.
Por lo tanto, se espera que la falta de profesionales capacitados que realicen biopsias líquidas suponga un desafío para el crecimiento del mercado.
Desarrollo reciente
- En enero de 2022, Exact Sciences Corporation anunció la adquisición de Prevention Genetics, un laboratorio de pruebas genéticas, para complementar su cartera de diagnóstico avanzado del cáncer y respaldar su ingreso a las pruebas de cáncer hereditario (HCT).
Alcance del mercado de biopsia líquida en Oriente Medio y África
El mercado de biopsia líquida de Oriente Medio y África se clasifica en nueve segmentos notables que son producto, tipo de biofabricante, tipo de muestra, tipo analítico, tipo de aplicación, aplicación clínica, tecnología, usuario final y canal de distribución. El crecimiento entre estos segmentos lo ayudará a analizar los segmentos de crecimiento del mercado en las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Producto
- Instrumentos
- Consumibles y accesorios
- Servicios y software
Según el producto, el mercado está segmentado en instrumentos, consumibles y accesorios, servicios y software.
Tipo de biofabricante
- Células tumorales circulantes (CTCS)
- ADN libre circulante (CFDNA)
- ARN libre de células
- Exosomas
- Vesículas extracelulares
- Otros
Según el tipo de biofabricante, el mercado está segmentado en células tumorales circulantes (CTCS), ADN libre de células circulantes (CFDNA), ARN libre de células, vesículas extracelulares, exosomas y otros.
Tipo de muestra
- Basado en muestras de sangre
- Basado en muestra de orina
- Muestras de saliva y otros fluidos tisulares
- Otros
Según el tipo de muestra, el mercado se segmenta en muestras de sangre, muestras de orina, muestras de saliva y otros fluidos tisulares, entre otros.
Tipo Analítico
- Molecular
- Proteómica
- Histología/Imagenología
Sobre la base del tipo de análisis, el mercado está segmentado en molecular, proteómica e histología/imagen.
Tipo de aplicación
- Aplicaciones contra el cáncer
- Aplicaciones no relacionadas con el cáncer
Según el tipo de aplicación, el mercado está segmentado en aplicaciones oncológicas y aplicaciones no oncológicas.
Aplicación clínica
- Examen de rutina
- Selección de terapia
- Seguimiento del tratamiento
- Monitoreo de recurrencia
- Evaluación del paciente
- Otros
Sobre la base de la aplicación clínica, el mercado está segmentado en detección de rutina, evaluación del paciente, selección de terapia, seguimiento del tratamiento, seguimiento de la recurrencia y otros.
Tecnología
- Análisis paralelo de múltiples genes
- Análisis de un solo gen
Sobre la base de la tecnología, el mercado está segmentado en análisis paralelo de múltiples genes y análisis de un solo gen.
Usuario final
- Hospitales
- Laboratorios de referencia
- Centros de diagnóstico
- Centros de investigación e institutos académicos
- Otros
Según el usuario final, el mercado se segmenta en hospitales, laboratorios de referencia, centros de diagnóstico, centros de investigación e institutos académicos, y otros.
Canales de distribución
- Licitación directa
- Distribuidor externo
- Otros
Sobre la base del canal de distribución, el mercado se segmenta en licitación directa, distribuidor externo y otros.
Análisis y perspectivas regionales del mercado de biopsia líquida en Oriente Medio y África
Se analiza el mercado de biopsia líquida de Oriente Medio y África, y se proporcionan información y tendencias del tamaño del mercado según el producto, el tipo de biofabricante, el tipo de muestra, el tipo analítico, el tipo de aplicación, la aplicación clínica, la tecnología, el usuario final y el canal de distribución.
Los países cubiertos en este informe de mercado son Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto y el resto de Medio Oriente y África.
In 2023, South Africa is expected to dominate the Middle East and Africa region due to technological advancements in liquid biopsy platforms in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Liquid Biopsy Market Share Analysis
The Middle East and Africa liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, brand analysis, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Middle East and Africa liquid biopsy market.
Some of the major players in the Middle East and Africa liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., and Sysmex Inostics Inc. among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS:
6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
7.2 RESTRAINTS
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS
7.2.2 LACK OF STANDARDIZED GUIDELINES
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.2.1 TEST KITS
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
8.2.1.2 DNA ISOLATION KIT
8.2.1.3 OTHERS
8.2.2 COLLECTION TUBES
8.2.2.1 50 PIECES
8.2.2.2 100 PIECES
8.2.3 ASSAYS
8.2.3.1 FLEXIBLE REAGENTS
8.2.3.2 SCALABLE REAGENTS
8.2.3.3 OTHERS
8.2.4 CONTROL KIT
8.2.5 OTHERS
8.3 INSTRUMENTS
8.3.1 ANALYZERS
8.3.2 SYSTEMS
8.3.3 OTHERS
8.4 SERVICES & SOFTWARE
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
8.4.2 DPCR ANALYSIS SOFTWARE
8.4.3 CASTPCR ANALYSIS SOFTWARE
8.4.4 OTHERS
9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
10.5 OTHERS
11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.2.1 NGS
11.2.2 PCR
11.2.3 MICROARRAY
11.2.4 PROTEOMICS
11.2.5 OTHERS
11.3 PROTEOMIC
11.3.1 NGS
11.3.2 PCR
11.3.3 MICROARRAY
11.3.4 PROTEOMICS
11.3.5 OTHERS
11.4 HISTOLOGY/IMAGING
12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.2.1 LUNG
12.2.2 BREAST
12.2.2.1 EARLY BREAST CANCER
12.2.2.2 ADVANCED BREAST CANCER
12.2.3 COLORECTAL
12.2.4 PROSTRATE
12.2.5 LIVER
12.2.6 OTHERS
12.3 NON-CANCER APPLICATIONS
12.3.1 PRENATAL DIAGNOSIS
12.3.2 PERSONALIZED IMMUNOTHERAPY
12.3.3 OTHERS
13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.4.1 EARLY-STAGE DISEASE
13.4.2 LATE-STAGE/METASTATIC DISEASE
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 MULTI-GENE-PARALLEL ANALYSIS
14.3 SINGLE GENE ANALYSIS
15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTIC CENTERS
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
15.6 OTHERS
16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 U.A.E.
17.1.4 EGYPT
17.1.5 ISRAEL
17.1.6 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GUARDANT HEALTH
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 THERMO FISHER SCIENTIFIC INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 EXACT SCIENCE CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 QIAGEN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ANGLE PLC (2022)
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BIOCEPT, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BIO-RAD LABORATORIES, INC. (2022)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 EPIC SCIENCES
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 FLUXION BIOSCIENCES INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 ILLUMINA, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 SWOT ANALYSIS
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 JOHNSON & JOHNSON PRIVATE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 MDXHEALTH
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MENARINI SILICON BIOSYSTEMS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 NATERA, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 NEOGENOMICS LABORATORIES
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 ONCOCYTE CORPORATION
19.18.1 COMPANY PROFILE
19.18.2 SERVICE PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 PATHAI
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PREDICINE
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.21 STRECK
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYSMEX INOSTICS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE
TABLE 2 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 61 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 63 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 65 MIDDLE EAST AND AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 68 MIDDLE EAST AND AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 SOUTH AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 87 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 SOUTH AFRICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 90 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 92 SOUTH AFRICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 93 SOUTH AFRICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 96 SOUTH AFRICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 97 SOUTH AFRICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 103 SOUTH AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 SOUTH AFRICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 105 SOUTH AFRICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 SOUTH AFRICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 107 SOUTH AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 SOUTH AFRICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 SOUTH AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 110 SOUTH AFRICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 SOUTH AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 SAUDI ARABIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 116 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 SAUDI ARABIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 119 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 121 SAUDI ARABIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 122 SAUDI ARABIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 125 SAUDI ARABIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 126 SAUDI ARABIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 128 SAUDI ARABIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 129 SAUDI ARABIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 132 SAUDI ARABIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 133 SAUDI ARABIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 134 SAUDI ARABIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 135 SAUDI ARABIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 SAUDI ARABIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 SAUDI ARABIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 SAUDI ARABIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 139 SAUDI ARABIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 SAUDI ARABIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 U.A.E. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.A.E. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.A.E. CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 U.A.E. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 145 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 U.A.E. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 148 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 U.A.E. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 151 U.A.E. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 154 U.A.E. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 155 U.A.E. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 U.A.E. LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.A.E. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 U.A.E. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.A.E. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.A.E. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.A.E. LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.A.E. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 163 U.A.E. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 164 U.A.E. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.A.E. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.A.E. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.A.E. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 U.A.E. LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 U.A.E. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 EGYPT LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 EGYPT CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 EGYPT CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 EGYPT LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 174 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 EGYPT TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 177 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 EGYPT COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 180 EGYPT ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 183 EGYPT INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 184 EGYPT SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 EGYPT LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 186 EGYPT LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 187 EGYPT LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 188 EGYPT MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 189 EGYPT PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 190 EGYPT LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 EGYPT CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 EGYPT BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 EGYPT NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 194 EGYPT LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 195 EGYPT TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 EGYPT LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 197 EGYPT LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 198 EGYPT LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 199 ISRAEL LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 ISRAEL CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 ISRAEL CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 ISRAEL LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 203 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 ISRAEL TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 206 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 207 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 208 ISRAEL COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 ISRAEL ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 ISRAEL INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 213 ISRAEL SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 214 ISRAEL LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 215 ISRAEL LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 216 ISRAEL LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 217 ISRAEL MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 218 ISRAEL PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 219 ISRAEL LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 ISRAEL CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 ISRAEL BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 ISRAEL NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 223 ISRAEL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 ISRAEL TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 225 ISRAEL LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 226 ISRAEL LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 227 ISRAEL LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET
FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY
FIGURE 15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, 2022
FIGURE 16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022
FIGURE 20 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)
FIGURE 22 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022
FIGURE 24 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022
FIGURE 28 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022
FIGURE 32 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022
FIGURE 36 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022
FIGURE 40 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, 2022
FIGURE 44 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: SNAPSHOT (2022)
FIGURE 52 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2022)
FIGURE 53 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)
FIGURE 56 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
